Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Centessa Pharmaceuticals PLC ADR (CNTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CNTA (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 63.65% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.76B USD | Price to earnings Ratio - | 1Y Target Price 31.25 |
Price to earnings Ratio - | 1Y Target Price 31.25 | ||
Volume (30-day avg) 1023103 | Beta 1.55 | 52 Weeks Range 7.75 - 19.09 | Updated Date 04/2/2025 |
52 Weeks Range 7.75 - 19.09 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-24 | When - | Estimate -0.355 | Actual -0.5849 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.82% | Return on Equity (TTM) -73.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1397077937 | Price to Sales(TTM) 233.74 |
Enterprise Value 1397077937 | Price to Sales(TTM) 233.74 | ||
Enterprise Value to Revenue 231.72 | Enterprise Value to EBITDA 1.12 | Shares Outstanding 133184000 | Shares Floating 91689433 |
Shares Outstanding 133184000 | Shares Floating 91689433 | ||
Percent Insiders 1.54 | Percent Institutions 96.14 |
Analyst Ratings
Rating 4.78 | Target Price 28.57 | Buy 2 | Strong Buy 7 |
Buy 2 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Centessa Pharmaceuticals PLC ADR
Company Overview
History and Background
Centessa Pharmaceuticals was formed in 2021 through the merger of 10 private biotech companies. The goal was to create a more efficient and diversified drug development engine. The company focuses on discovering and developing innovative therapies across multiple therapeutic areas.
Core Business Areas
- Hematology-Oncology: Focuses on developing therapies for various blood cancers and solid tumors.
- Immunology: Developing treatments targeting immune-related disorders.
- Neuroscience: Researching and developing therapies for neurological conditions.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure is built around a decentralized model, fostering innovation across its various subsidiary companies.
Top Products and Market Share
Key Offerings
- CTX-8371: An oral small molecule for the treatment of myelofibrosis. Currently in clinical development. Market share data is not yet available as it is not yet on the market. Competitors include Incyte (Jakafi) and Sierra Oncology (Momelotinib).
- IMG-7289 (iometinib): A lysine-specific demethylase 1 (LSD1) inhibitor being developed for hematologic malignancies. Currently in clinical development. Market share data is not yet available as it is not yet on the market. Competitors include Trisenox.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. It's driven by innovation and the need for new therapies to address unmet medical needs.
Positioning
Centessa Pharmaceuticals aims to differentiate itself through its diversified portfolio and decentralized R&D model. It seeks to accelerate drug development and improve clinical outcomes.
Total Addressable Market (TAM)
The total addressable market for Centessa's target therapeutic areas is substantial, estimated in the billions of dollars annually. Centessa is positioning itself to capture a share of this market through the development of novel therapies.
Upturn SWOT Analysis
Strengths
- Diversified pipeline
- Experienced leadership team
- Decentralized R&D model
- Strong financial backing
Weaknesses
- Early stage pipeline
- High cash burn rate
- Reliance on clinical trial success
- Complex organizational structure
Opportunities
- Potential for breakthrough therapies
- Strategic partnerships and acquisitions
- Expansion into new therapeutic areas
- Accelerated regulatory pathways
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- INCY
- MRTX
- SIOX
Competitive Landscape
Centessa faces strong competition from established pharmaceutical companies with approved therapies and larger R&D budgets. Its success depends on demonstrating superior efficacy and safety in its clinical trials.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline expansion and clinical trial initiations.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing key clinical programs and exploring strategic partnerships.
Summary
Centessa Pharmaceuticals is a high-risk, high-reward clinical-stage company with a diversified pipeline. The company's success hinges on the outcome of its clinical trials. Its decentralized R&D model is innovative but also carries organizational complexity and high operational costs. Success will come from positive clinical data and efficient resource allocation.
Similar Companies
ARRY
Array Technologies Inc
ARRY
Array Technologies Inc
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
INCY
Incyte Corporation
INCY
Incyte Corporation
Sources and Disclaimers
Data Sources:
- Centessa Pharmaceuticals PLC ADR Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and due diligence. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Centessa Pharmaceuticals PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-05-28 | CEO & Director Dr. Saurabh Saha M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 77 | Website https://www.centessa.com |
Full time employees 77 | Website https://www.centessa.com | ||
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.